Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Pharmaceutical Research
|
February 27, 2004
A cell fractionation approach for the quantitative analysis of subcellular drug disposition
Muralikrishna Duvvuri, Wenhong Feng, Amanda Mathis, et al.
Clinical and Translational Science
|
February 25, 2022
Population pharmacokinetic modeling and simulations of berotralstat for prophylactic treatment of attacks of hereditary angioedema
Amanda Mathis, Mark Sale, Melanie Cornpropst, et al.
Clinical Pharmacology in Drug Development
|
February 19, 2022
Pharmacokinetics and Safety of the Nucleoside Analog Antiviral Drug Galidesivir Administered to Healthy Adult Subjects
Amanda Mathis, David Collins, Sylvia Dobo, et al.
Biochimie
|
March 18, 2008
Antiparasitic compounds that target DNA
W David Wilson, Farial A Tanious, Amanda Mathis, et al.
Antiviral Research
|
September 22, 2021
An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral
Justin G Julander, James F Demarest, Ray Taylor, et al.
Current Medicinal Chemistry. Anti-Cancer Agents
|
August 17, 2005
Dications that target the DNA minor groove: compound design and preparation, DNA interactions, cellular distribution and biological activity
W David Wilson, Binh Nguyen, Farial A Tanious, et al.
Viruses
|
January 22, 2022
Activity of Galidesivir in a Hamster Model of SARS-CoV-2
Ray Taylor, Richard Bowen, James F Demarest, et al.
Journal of Clinical Pharmacology
|
April 28, 2025
First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Complement Factor D Inhibitor BCX9930 in Healthy Participants
Matthew Davidson, Xilin Chen, Amanda Mathis, et al.
Antiviral Research
|
June 5, 2018
Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters
Jonna B Westover, Amanda Mathis, Ray Taylor, et al.
Journal of Medicinal Chemistry
|
November 10, 2012
Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase
Pek Chong, Paul Sebahar, Michael Youngman, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Pharmaceutical Research
|
February 27, 2004
A cell fractionation approach for the quantitative analysis of subcellular drug disposition
Muralikrishna Duvvuri, Wenhong Feng, Amanda Mathis, et al.
Clinical and Translational Science
|
February 25, 2022
Population pharmacokinetic modeling and simulations of berotralstat for prophylactic treatment of attacks of hereditary angioedema
Amanda Mathis, Mark Sale, Melanie Cornpropst, et al.
Clinical Pharmacology in Drug Development
|
February 19, 2022
Pharmacokinetics and Safety of the Nucleoside Analog Antiviral Drug Galidesivir Administered to Healthy Adult Subjects
Amanda Mathis, David Collins, Sylvia Dobo, et al.
Biochimie
|
March 18, 2008
Antiparasitic compounds that target DNA
W David Wilson, Farial A Tanious, Amanda Mathis, et al.
Antiviral Research
|
September 22, 2021
An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral
Justin G Julander, James F Demarest, Ray Taylor, et al.
Current Medicinal Chemistry. Anti-Cancer Agents
|
August 17, 2005
Dications that target the DNA minor groove: compound design and preparation, DNA interactions, cellular distribution and biological activity
W David Wilson, Binh Nguyen, Farial A Tanious, et al.
Viruses
|
January 22, 2022
Activity of Galidesivir in a Hamster Model of SARS-CoV-2
Ray Taylor, Richard Bowen, James F Demarest, et al.
Journal of Clinical Pharmacology
|
April 28, 2025
First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Complement Factor D Inhibitor BCX9930 in Healthy Participants
Matthew Davidson, Xilin Chen, Amanda Mathis, et al.
Antiviral Research
|
June 5, 2018
Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters
Jonna B Westover, Amanda Mathis, Ray Taylor, et al.
Journal of Medicinal Chemistry
|
November 10, 2012
Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase
Pek Chong, Paul Sebahar, Michael Youngman, et al.
Page
of 2